Skip to main content
Top
Published in: Annals of Surgical Oncology 10/2013

01-10-2013 | Breast Oncology

Axillary Reverse Mapping: A Prospective Study in Women with Clinically Node Negative and Node Positive Breast Cancer

Authors: Carol Connor, MD, Marilee McGinness, MD, Joshua Mammen, MD, PhD, Lori Ranallo, ARNP, Stephanie LaFaver, ARNP, Jennifer Klemp, PhD, MPH, Fang Fan, MD, PhD, Jonathan Mahnken, PhD

Published in: Annals of Surgical Oncology | Issue 10/2013

Login to get access

Abstract

Background

The primary aim of axillary reverse mapping (ARM) is to prevent lymphedema by preserving arm versus breast axillary lymphatics. Concerns regarding feasibility and oncologic safety have limited the adoption of the technique. This prospective study was undertaken to investigate ARM in clinically node negative and node positive breast cancer patients.

Methods

A total of 184 patients underwent 212 ARM procedures: 155 sentinel lymph node biopsies (SLNB) without axillary lymph node dissection (ALND) (group 1) and 57 ALNDs with/without SLNB (group 2). ARM lymphatics were not preserved if they were a SLN, directly entered a SLN, or were within ALND boundaries during ALND.

Results

SLN with radioisotope alone was successful in 92 % of procedures (181 of 197). ARM identification was 47 % (73 of 155) in group 1. Criteria were met in 30 % (47 of 155) for preservation, and 25 % (38 of 155) were preserved. Of those who met preservation criteria, 81 % (38 of 47) were preserved. In group 2, ARM identification was 72 % (41 of 57); 7 met criteria for preservation and were preserved. Of the ARM nodes, 10 % (22 of 212) were SLNs (crossover). ARM nodes contained metastatic disease in one crossover and two nonsentinel ARM nodes in clinically node positive patients with N2/N3 disease.

Conclusions

ARM is a feasible technique for identification and preservation of axillary arm lymphatics with an acceptable incidence of SLN crossover. A larger sample size is needed to determine if ARM can reduce the incidence of lymphedema in patients undergoing SLNB alone and to confirm the absence of ARM metastases in clinically node negative patients undergoing ALND.
Literature
1.
go back to reference Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC Trial. J Natl Cancer Inst. 2006;98:599–609.PubMedCrossRef Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC Trial. J Natl Cancer Inst. 2006;98:599–609.PubMedCrossRef
2.
go back to reference Ashikaga T, Krag DN, Land SR, Julian TB, Anderson SJ, Brown AM, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102:111–8.PubMedCrossRef Ashikaga T, Krag DN, Land SR, Julian TB, Anderson SJ, Brown AM, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102:111–8.PubMedCrossRef
3.
go back to reference Thompson M, Korourian S, Henry-Tillman R, Adkins L, Mumford S, Westbrook K, et al. Axillary reverse mapping (ARM): a new concept to identify and enhance lymphatic preservation. Ann Surg Oncol. 2007;14:1890–5.PubMedCrossRef Thompson M, Korourian S, Henry-Tillman R, Adkins L, Mumford S, Westbrook K, et al. Axillary reverse mapping (ARM): a new concept to identify and enhance lymphatic preservation. Ann Surg Oncol. 2007;14:1890–5.PubMedCrossRef
4.
go back to reference Boneti C, Korourian S, Diaz Z, Santiago C, Mumford S, Adkins L, et al. Scientific Impact Award: Axillary reverse mapping (ARM) to identify and protect lymphatics draining the arm during axillary lymphadenectomy. Am J Surg. 2009;198:482–7.PubMedCrossRef Boneti C, Korourian S, Diaz Z, Santiago C, Mumford S, Adkins L, et al. Scientific Impact Award: Axillary reverse mapping (ARM) to identify and protect lymphatics draining the arm during axillary lymphadenectomy. Am J Surg. 2009;198:482–7.PubMedCrossRef
5.
go back to reference Noguchi M, Noguchi M, Nakano Y, Ohno Y, Kosaka T. Axillary reverse mapping using a fluorescence imaging system in breast cancer. J Surg Oncol. 2012;105:229–34.PubMedCrossRef Noguchi M, Noguchi M, Nakano Y, Ohno Y, Kosaka T. Axillary reverse mapping using a fluorescence imaging system in breast cancer. J Surg Oncol. 2012;105:229–34.PubMedCrossRef
6.
go back to reference Bedrosian I, Babiera GV, Mittendorf EA, Kuerer HM, Pantoja L, Hunt KK, et al. A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer. 2010;116:2543–8.PubMed Bedrosian I, Babiera GV, Mittendorf EA, Kuerer HM, Pantoja L, Hunt KK, et al. A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer. 2010;116:2543–8.PubMed
7.
go back to reference Nos C, Kaufmann G, Clough KB, Collignon MA, Zerbib E, Cusumano P, et al. Combined axillary reverse mapping (ARM) technique for breast cancer patients requiring axillary dissection. Ann Surg Oncol. 2008;15:2550–5.PubMedCrossRef Nos C, Kaufmann G, Clough KB, Collignon MA, Zerbib E, Cusumano P, et al. Combined axillary reverse mapping (ARM) technique for breast cancer patients requiring axillary dissection. Ann Surg Oncol. 2008;15:2550–5.PubMedCrossRef
8.
go back to reference Gobardhan PD, Wijsman JH, Van Dalen T, Klompenhouwer EG, van der Schelling GP, Los J, Voogd AC, et al. ARM: axillary reverse—the need for selection of patients. Eur J Surg Oncol. 2012;38:657–67.PubMedCrossRef Gobardhan PD, Wijsman JH, Van Dalen T, Klompenhouwer EG, van der Schelling GP, Los J, Voogd AC, et al. ARM: axillary reverse—the need for selection of patients. Eur J Surg Oncol. 2012;38:657–67.PubMedCrossRef
9.
go back to reference Casabona F, Bogliolo S, Menanda M, Sala P, Villa G, Ferrero S. Feasibility of axillary reverse mapping during sentinel node biopsy in breast cancer patients. Ann Surg Oncol. 2009;16:2459–63.PubMedCrossRef Casabona F, Bogliolo S, Menanda M, Sala P, Villa G, Ferrero S. Feasibility of axillary reverse mapping during sentinel node biopsy in breast cancer patients. Ann Surg Oncol. 2009;16:2459–63.PubMedCrossRef
10.
go back to reference Giuliano AE, McCall L, Beitsche P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases. Ann Surg. 2010;252:426–33.PubMed Giuliano AE, McCall L, Beitsche P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases. Ann Surg. 2010;252:426–33.PubMed
Metadata
Title
Axillary Reverse Mapping: A Prospective Study in Women with Clinically Node Negative and Node Positive Breast Cancer
Authors
Carol Connor, MD
Marilee McGinness, MD
Joshua Mammen, MD, PhD
Lori Ranallo, ARNP
Stephanie LaFaver, ARNP
Jennifer Klemp, PhD, MPH
Fang Fan, MD, PhD
Jonathan Mahnken, PhD
Publication date
01-10-2013
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 10/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-3113-4

Other articles of this Issue 10/2013

Annals of Surgical Oncology 10/2013 Go to the issue